Guideline Summary for Chronic Idiopathic Constipation in Adults

Initial Assessment and Baseline Measures

• Adults with chronic idiopathic constipation should be screened for low fluid intake; those in the lowest quartile of daily fluid consumption have a higher likelihood of constipation【@1】.
• Fiber supplements should be taken with 8–10 oz of fluid to optimize efficacy【@1】.

First‑Line Pharmacologic Therapy (PEG)

• The American Gastroenterological Association (AGA) and American College of Gastroenterology (ACG) strongly recommend polyethylene glycol (PEG) 17 g once daily as the initial pharmacologic treatment for chronic idiopathic constipation, citing moderate‑certainty evidence of durable symptom improvement over 6 months【@1】.
• Start PEG 3350 at 17 g (one capful) mixed in 4–8 oz of liquid; dose may be titrated upward after 1–2 weeks if response is inadequate【@4】.
• PEG therapy is associated with mild‑to‑moderate adverse effects such as abdominal distension, loose stools, flatulence, and nausea【@1】.
• PEG should be used only under direct physician supervision in patients with chronic kidney disease because of potential fluid and electrolyte disturbances【@4】.

Fiber Supplementation (Adjunct or Initial Step)

• Psyllium is the preferred soluble fiber for mild‑to‑moderate constipation, although the supporting evidence is of low quality【@1】.
• Dietary fiber increases stool weight through water retention and bacterial fermentation, which secondarily shortens colonic transit time【@1】.
• Finely ground wheat bran should be avoided because it reduces stool water content and can harden stools【@1】.
• The most common side effect of fiber supplementation is flatulence【@1】.
• Fiber products such as Metamucil are not effective for opioid‑induced constipation and are not recommended for that indication【@2】【@3】.

Alternative Osmotic Laxatives (When PEG Fails or Is Not Tolerated)

• Lactulose (30–60 mL daily) creates a low‑pH osmotic diarrhea useful for refractory constipation【@2】.
• Magnesium hydroxide (30–60 mL daily) provides rapid bowel evacuation【@2】.
• Magnesium citrate is an additional osmotic option【@2】.
• Magnesium‑based laxatives must be avoided in patients with renal insufficiency due to the risk of hypermagnesemia【@6】.

Stimulant Laxatives (Add‑On Therapy)

• Senna (2 tablets each morning; max 8–12 tablets/day) can be added when osmotic agents alone are insufficient【@2】.
• Bisacodyl (2–3 tablets orally daily or suppository daily) is another stimulant option【@2】.
• Stimulant laxatives enhance intestinal motility by stimulating the myenteric plexus and reducing colonic water absorption【@5】.
• They should be avoided in patients with intestinal obstruction; excessive use may cause diarrhea and hypokalemia【@5】.

Rescue Therapy for Persistent Constipation

• Before escalation, reassess for mechanical obstruction and fecal impaction【@2】.
• Sorbitol (30 mL every 2 h × 3, then PRN) can be used for rapid relief【@2】.
• Enemas (Fleet, saline, or tap water) provide acute evacuation when needed【@2】.
• Metoclopramide (10–20 mg orally) may be employed as a pro‑kinetic adjunct【@2】.

Prescription Secretagogues (Refractory Cases)

• Lubiprostone may offer additional benefit, particularly for abdominal pain relief, in patients unresponsive to conventional laxatives【@4】.
• Prucalopride, a selective 5‑HT₄ receptor agonist, is effective for chronic constipation without associated cardiac risks【@5】.

Special Populations

Opioid‑Induced Constipation

• Initiate a prophylactic regimen of a stool softener plus a stimulant laxative (e.g., senna) when starting opioid therapy【@2】.
• Increase the laxative dose proportionally when the opioid dose is escalated【@2】.
• Methylnaltrexone (0.15 mg/kg subcutaneously) is recommended for patients with advanced illness who have an inadequate response to conventional laxatives【@2】.
• Naloxone (1.6 mg subcutaneously daily) or alternating‑day methylnaltrexone may counteract opioid‑induced dysmotility【@5】.

Severe Small‑Bowel Dysmotility (e.g., Systemic Sclerosis)

• Octreotide (50–100 µg subcutaneously once or twice daily) can produce dramatic improvement within 48 hours when other treatments have failed【@5】.

Psyllium (Soluble Fiber) as First‑Line Therapy for Functional Constipation in Adults

Recommendations

• The 2023 AGA‑ACG guidelines conditionally recommend psyllium as the first‑line treatment for functional constipation in adults, based on low‑quality evidence; insoluble fiber may worsen symptoms. 1
• Psyllium is the only fiber supplement with consistent efficacy for chronic constipation according to the same AGA‑ACG guidance. 1

Dosing and Administration

• Each psyllium dose should be taken with 8–10 oz (≈240–300 mL) of fluid to ensure adequate hydration and prevent blockage. 1
• Initiate psyllium at standard doses and titrate upward based on clinical response (minimum effective dose generally >10 g/day, though exact titration details are not cited).

Mechanism of Action

• Psyllium is a soluble, gel‑forming fiber that increases stool bulk by (1) its physical presence, (2) water retention within the gel matrix, and (3) promotion of bacterial mass through partial fermentation, resulting in softer, bulkier stools that are easier to pass. 1

Fibers to Avoid

• Insoluble fibers (e.g., wheat bran) should be avoided because they can decrease stool water content, harden stools, and increase bloating without improving bowel frequency. 1
• Highly fermentable soluble fibers (e.g., inulin) lack sufficient water‑holding capacity and therefore do not provide a laxative effect. 1

Clinical Implementation

• Assess baseline dietary fiber intake before starting supplementation. 2
• Screen for low fluid intake; patients in the lowest quartile of daily fluid consumption have higher constipation rates. 1
• Target fluid‑intake improvement specifically in those identified with low consumption to enhance fiber efficacy. 1
• Start psyllium as first‑line therapy for mild‑to‑moderate constipation, especially when baseline fiber intake is low; it is low‑risk, inexpensive, and readily available. 1
• Emphasize adequate hydration with each dose to prevent potential intestinal blockage. 1

Escalation to Polyethylene Glycol (PEG)

• If psy­llium fails to provide adequate relief after ≥4 weeks, add or switch to PEG 17 g once daily. 1
• PEG receives a strong recommendation with moderate‑certainty evidence for chronic idiopathic constipation. 1
• Combining PEG with psyllium may yield additive benefits in bowel habit improvement. 1

Adverse Effects

• Flatulence is the most common side effect of fiber supplementation, occurring with all fiber types and being more pronounced with highly fermentable fibers. 1

Evidence Quality and Limitations

• The overall body of evidence for fiber in constipation is low quality, derived mainly from small, older studies (30–40 years) that predominantly enrolled women. 1
• Despite these limitations, the 2023 AGA‑ACG guidelines endorse a trial of fiber supplementation because it is safe, inexpensive, and accessible. 1
• Among fiber types, psyllium has the strongest (though still low‑quality) data for constipation relief. 1
• Evidence for wheat bran and inulin is limited and uncertain. 1

Special Populations – IBS‑C

• The 2021 ACG guidelines make a strong recommendation for soluble fiber (e.g., psyllium) in constipation‑predominant irritable bowel syndrome (IBS‑C), based on a meta‑analysis of 15 RCTs showing benefit with minimal adverse effects. 3
• Soluble fiber is specifically preferred over insoluble fiber for IBS‑C patients. 3

Gradual Introduction of Fiber to Prevent Intolerance

Evidence Supporting a Slow Start